RhoVac is a biotechnology company conducting research and development in immunotherapy, more specifically – on therapeutic cancer vaccines. The company’s primary focus is to develop a drug with the potential to prevent or limit metastases in metastatic cancers.
Group Relationships and Shareholdings
The RhoVac Group comprises parent company RhoVac AB and the wholly-owned subsidiary RhoVac ApS. All operations are conducted through the subsidiary. RhoVac AB’s only business activity is ownership of the RhoVac ApS subsidiary. RhoVac has no shareholdings in any companies other than the above.
RhoVac intends to license or sell all, or part of, operations at the earliest after completion of Phase I/II Studies have been completed. The Board continually evaluates how best to create value in the company, concentrating on generating value by licensing or selling operations.
A brief overview of RhoVac’s history is presented below. RhoVac ApS was established in 2007. RhoVac AB, the group parent company, was established November 2015.
|2007||RhoVac ApS established and commences operations.|
|2007||National patent application submitted.|
|2008||International patent application submitted.|
|2009||RhoVac completes toxicology study (non-GLP) with good results.|
|2009||RhoVac is approved for an Innovation loan from Nordea Fonden (DK).|
|2012||RhoVac receives development funding from the Danish Agency for Science, Technology and Innovation.|
|2013||Patent granted in Australia.|
|2014||RhoVac establishes cooperation with Ventac Partners.|
|2015||Patent granted in Japan.|
|2015||Patent granted in USA.|
|2015||Process development of the pharmaceutical substance and analytical development.|
|2015||RhoVac initiates toxicology study in accordance with GLP.|
|2015||First batch of the pharmaceutical substance is produced and stability studies commence.|
|2015||RhoVac AB established.|
|2016||RhoVac AB Listed on Spotlight Stock Market.|
|2016||Report submitted on the clear Toxicology Study.|
|2016||Production of pharmaceutical drug substance and pharmaceutical product concluded.|
|2016||Application for clinical trial submitted.|
|2016||Research collaboration with the University of Tübingen in Germany commenced.|
|2017||Approval granted for start of Clinical Phase I/II Study.|
|2017||Patent granted by the European Patent Office.|
|2017||Second patent granted by the Japanese Patent Office.|
|2017||First patient treated in the Clinical Phase I/II Study|
|2017||Complete patient recruitment to ongoing Clinical Phase I/II study|
|2017||Treatment of all patients in the Clinical Phase I/II Study|
|2017||Defintion of the Clinical Phase IIb programme|
|2018||Completion of treament for all patients in the Clinical Phase I/II study|
|2018||Summary and Final Report of the Clinical Phase I/II Study|